Vector BioMed COO Mike Kadan On Reinventing Viral Vector Manufacturing For A Decentralized Gene Therapy Future

In this exclusive interview with BioPharma BoardRoom, Mike Kadan, Ph.D., MBA, Chief Operating Officer of Vector BioMed, explains how the company is reshaping the landscape of viral vector manufacturing. Through a modular, purpose-built platform, Vector BioMed delivers high-quality lentiviral vectors at scale — faster, more affordably, and with uncompromising quality. Kadan outlines how this model challenges the limitations of traditional CDMOs by accelerating timelines and enabling decentralized manufacturing, especially in underserved regions.

He also discusses Vector BioMed’s involvement in global partnerships, including initiatives with Caring Cross in Brazil and Turkey, aimed at expanding access to advanced cell and gene therapies. The company’s infrastructure is positioned not just as a manufacturing solution, but as a catalyst for equitable global healthcare innovation.

Note: This article was originally published on BioPharma BoardRoom.